NCT05757596 - Study of VSA001 Injection in Chinese Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

September 25, 2023

Study Completion Date

December 31, 2023

Conditions

Healthy Adult Volunteers

Interventions

DRUG

VSA001 injection

The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.

DRUG

Placebo

0.9% Saline, volume matched

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijing